ethylene diamine tetra-acetic acid (E.D.T.A.) (Bessman, Ried, and Rubin, 1952) .
This compound has the property of binding lead in a non-ionic form which is rapidly excreted in the urine. In this country reports have appeared on its intravenous use (Giles, Moore, and Still, 1955; Markus and Spencer, 1955; Travers, Rendle-Short, and Harvey, 1956; Leckie and Tompsett, 1958 ) and on its intramuscular use (Shrand, 1961) .
Small factories working with lead compounds often have inadequate protective devices for their workers or minimal medical supervision. This can lead either to cases of frank lead poisoning or to excessive lead absorption by the men working with the compounds. Two small factories in this area were found to have inadequate safety precautions after several cases of lead poisoning had occurred among their workers. These cases were treated with calcium disodium ethylene diamine tetra-acetate (calcium disodium versenatet) intravenously. All made good recoveries after the removal of large amounts of lead. Complete overhaul of the processes and protective devices was made in the factory.
In addition to the more severely affected men several others were found to have absorbed excessive amounts of lead to such a degree as to require treatment. As conditions at the factory were so rapidly improving and the men did not wish to stay off work, mainly for economic reasons, oral calcium disodium versenate M a, used. The men were allowed to remain at the factory, under close medical supervision, working at the less hazardous processes.
Methods of Investigation The assessment of the degree of lead absorption by lead workers was made on the results of haemoglobin, stippled cell, and reticulocyte estimations, the amount of lead in the urine and in the blood, the amount of coproporphyrin in the urine, and the presence of symptoms referable to lead. Haemoglobin was estimated by the alkaline haematin method and reticulocytes by Dacie's (1956) Case 3.-A.B. was a 34-year-old bachelor of rather untidy habits who had been working with lead compounds for three months. He was feeling tired and was rather unsteady on his feet. He had multiple neurofibromatosis. Laboratory tests showed haemoglobin 8-3 g./100 ml. (56%), reticulocytes 3 0%, stippled cells 17,700/million R.B.C., urine lead 940 jug./litre, blood lead 140, Lg./100 ml., coproporphyrin 4+. The blood film showed numerous stippled cells, many of which were shrunken and poikilocytotic. There were occasional normoblasts. Bilirubin 0 9 mg./100 ml.
He was treated with oral versenate in hospital and excreted 23-8 mg. of lead in seven days. Coproporphyrin was still high. His blood count at this time showed a great increase in stippled cells (56,000) and reticulocytes (94 %); haemoglobin was 9-2 g./100 ml. (62 %). He could not be detained in hospital any longer and remained at home for two weeks. At the end of this time his urine lead was averaging 400 ,4g./litre and coproporphyrin 4+, and he re-entered hospital for a course of intravenous versenate. His haemoglobin was 11 5 g./100 ml. (78%).
He received 2 g. versenate intravenously each day for five days in 500 ml. of saline.
He excreted 25-4 mg. of lead in six days. One week later his assessment showed haemoglobin 14-8 g./100 ml. (100%), blood lead 60ug./I00 ml., urine lead 160 tg./litre, coproporphyrin I +. Stippled cells absent.
Case 4.-T.G., a 40-year-old Pole, worked in various lead works for 12 years with no complaints. Haemoglobin 15-5 g./100 ml. (105 %), stippled cells 1,800/million R.B.C., blood lead 170 pg./100 ml., urine lead 540 jig./litre, coproporphyrin 4+. He excreted 1 19 mg. lead during his seven-day course of treatment. Later he showed haemoglobin 16-5 g./100 ml. (112 %), reticulocytes 2-6%, stippled cells 2,100/million R.B.C., urine lead 220,g./litre, blood lead 120 jAg./100 ml., coproporphyrintrace.
Case 5.-A.G.C., a 38-year-old man, was one of three brothers working with lead compounds. The other two had been treated six months previously with intravenous versenate for lead poisoning. A.G.C. presented with weakness and constipation. His haemoglobin was 14-8 g./100 ml. (100%), reticulocytes 2-3%, urine lead 140 ,ug./litre, and his urine contained a small amount of coproporphyrin. He received 4 g. versenate daily for one week and excreted 8 mg. of lead in his urine during this time. There was marked improvement in symptoms.
Urine lead fell to 70 t&g./litre; haemoglobin remained the same. Reticulocytes were 1-7 %. He continued at work, but three months later his haemoglobin was 13-6 g./100 ml., reticulocytes 3-4%, stippled cells 10,000/million R.B.C., urine lead 210 ,ug./litre, blood lead 120 ,ug./100 ml., coproporphyrin 1+. During a repeated course of versenate (present series) he excreted 12 6 mg. lead, and the haemoglobin rose to 14 5 g./100 ml. (98 %), reticulocytes 25%, stippled cells 13,200/million R.B.C., blood lead 90 jtg./100 ml., urine lead 120 ,ug./litre, coproporphyrin 1+.
Cases 6, 7, and 8.-These three cases worked in a small accumulator factory. E.A.K., age 59, for one and a half years, W.F., age 57, for nine years, and E.C.B., age 55, for three months. E.A.K. had episodes of constipation; the others were symptom-free. Laboratory findings were as follows:
Case 6.-E.A.K., haemoglobin 12-8 g./100 ml. (87%), stippled cells 12,000/million R.B.C., urine lead 240 t&g./litre, blood lead 130 tig./100 ml., coproporphyrin 1 +.
Oral versenate for seven days, lead excretion 15 7 mg.
Later haemoglobin 13-9 g./100 ml. (94%), stippled cells 9,100/million R.B.C., urine lead 240 ,tg./litre, blood lead 120 ,g./100 ml., coproporphyrin trace.
Case 7.-W.F., haemoglobin 10 6 g./100 ml. (72%), stippled cells 5,000/million R.B.C., urine lead 600 yg./litre, coproporphyrin 1 +, blood lead 1-0 jAg./100 ml. On oral versenate treatment seven-day lead excretion 13-7 mg. Later haemoglobin 12-3 g./100 ml. (83 %), stippled cells 4,600/million R.B.C., urine lead 240 ,g./litre, coproporphyrin trace, blood lead 80 pg./100 ml. 
Results
Oral versenate caused lead to be rapidly excreted in the urine. The lead content of the urine increased 500% within five hours (Fig. 1) . The daily excretion of lead rose to a maximum on the second day in five cases, the third day in one, and the fourth day in two. The concentration of lead in the urine rose to five to 11 times the base-line concentration. In two of the three men in whom extended collections of urine were made the output of lead continued at a decreasing rate up to the third post-treatment day, when the levels were 350 and 200,ug./day respectively. In the third man the excretion rate was still high at 1,066 ,ug. (880 ,tg./litre) on the eleventh day but by the twentieth day it had fallen to 180 Iug./litre (Fig. 2) .
The total lead excretion during the seven days of treatment varied from 7 6 to 23-8 mg., averaging 14 32 mg. lead per man.
Seven of the eight men showed a rise in haemoglobin level averaging 1-0 g. % (range 0-1 to 1-8 g.), and one showed a fall of 0-2 g. %.
In four the stippled cell count was lower at the end of treatment, but in the others it was higher. The urine lead concentration was lower after treatment than before in seven out of the eight men. Coproporphyrin levels tended to rise early in treatment, while large amounts of lead were being excreted, but fell rapidly later. Blood lead levels fell in five patients, remained the same in one, and rose in one.
Symptomatically the improvement was marked. One patient (Case 4) who felt "fine" before treatment felt "fine" after it. All the others volunteered feeling far more energetic, less tired, and having freer bowel actions. Case 3 had slight vomiting and diarrhoea after leaving hospital but the others reported no side-effects. In Fig. 3 we have expressed graphically the improvements in the patients after treatment with oral versenate. King and Thompson (1961) when measuring the amount of lead absorption in car workers, gave the result of each test a number of points depending on its deviation from the normal.
A normal result scored no points, a minor abnormality one, a gross abnormality four, and intermediate grades two or three points. The criteria they used are reproduced in the Table, and although the stippled cell and blood lead levels they used are rather low, we have adopted the same criteria to assess our results. Seven of the men showed a fall in the number of points they scored before and after treatment, the average fall being six points. Only in Case 3 was the same number of points scored before and after the course of treatment.
Discussion
We have confirmed that versenate taken orally causes a rapid rise in urinary lead excretion, maintains the excretion of lead, and that the effect persists in some cases for several days after treatment finishes. It also has a beneficial effect on the patient and his disease.
Previous reports on lead excretion in the urine after oral versenate follow a similar but not so uniform a pattern as in our cases. Sidbury, Bynum, and Fetz (1953) obtained increased excretions in three out of four patients, Bradley and Powell (1954) in three out of five. Bell, Gilliland, Boland, and Sullivan (1956) obtained excretion levels up to 4 mg. a day in three cases, one of whom had already received intravenous therapy with versenate. Shiels, Thomas, and Kearley (1956) in a careful study on six hospital patients obtained rises in levels up to 20 times those obtained before treatment.
The improvement in well-being of men on oral E.D.T.A. at work was shown by Manville and Moser (1955) and seven men treated for three weeks were freed of coproporphyrinuria. Cotter (1954) also recorded improvement.
One question mentioned in almost all previous papers on the use of oral versenate is the possibility of the versenate combining with lead in the lumen of the bowel with subsequent absorption and excretion into the urine. In other words, is the versenate really removing lead from the tissues or is it merely altering the route of excretion? The evidence for the latter view comes from animal studies.
Most of the lead excreted from lead-poisoned sheep is via the bile-ducts into the intestine, and only 20% of the excretion is via the urinary tract (Blaxter and Cowie, 1946) . In lead-poisoned rabbits oral versenate shifts the excretion of lead from the faeces to the urine (Rieders, 1954 Whatever the exact mechanism is, the undoubted improvement of the patient suggests that the net result is a removal of lead from the tissues.
Kehoe (1955) drew attention to the possible abuses of oral versenate and expressed fears lest the tablets were used to mask deficiencies in the protective equipment and the industrial processes. A simple prophylactic against lead poisoning has a great attraction for manufacturers when set against the often large outlay involved in installing protective devices, but it seems quite unjustifiable to expose men to the known hazards of lead compounds and at the same time to expose them to the yet unknown hazards of prolonged versenate therapy. For this reason we feel that the use of oral versenate should be limited. We have used it to treat cases of mild lead poisoning only when the processes at which the poisoning occurred have been modified or the men have been moved to a less hazardous process. When used in this way we have found it to be very effective in promoting lead excretion with the minimum of disturbance to the patient.
The output of lead in the urine following the intravenous use of versenate has been used in diagnosing excessive lead absorption (Leckie and Tompsett, 1958 
